Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR)
November 24, 2023 08:00 ET
|
Er-Kim Pharmaceuticals
Er-Kim Pharmaceuticals joins the industry to collaborate on the prevention of antimicrobial resistance (AMR) in support of World AMR Awareness Week
Global Antibiotic Resistance Markets, 2023-2027: Beyond Antibiotics - Exploring Cutting-Edge Trends in AMR Solutions
October 05, 2023 06:43 ET
|
Research and Markets
Dublin, Oct. 05, 2023 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Tinea Pedis Treatment Market Poised for Expansion: Opportunities in Rising Fungal Infections 2023 to 2030
September 29, 2023 07:23 ET
|
Research and Markets
Dublin, Sept. 29, 2023 (GLOBE NEWSWIRE) -- The "Tinea Pedis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2023-2028)" report has been added to ResearchAndMarkets.com's...
Antimicrobial Resistance Surveillance Market is Expected to Reach $7.7 billion | MarketsandMarkets.
September 21, 2023 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Sept. 21, 2023 (GLOBE NEWSWIRE) -- The Antimicrobial Resistance (AMR) Surveillance industry is poised for significant growth in the near future as the global healthcare community recognizes...
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:15 ET
|
OpGen, Inc.
Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D...
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
August 03, 2023 07:30 ET
|
OpGen, Inc.
ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter...
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
July 24, 2023 08:00 ET
|
AUROBAC THERAPEUTICS
Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr...
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
July 19, 2023 07:30 ET
|
OpGen, Inc.
All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
Veterinary Antimicrobial Susceptibility Testing Market Expected to Exceed USD 76.2 Bn by 2032: TMR Study
June 28, 2023 14:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 29, 2023 (GLOBE NEWSWIRE) -- The global veterinary antimicrobial susceptibility testing market was valued at US$ 37.6 Bn in 2021 and is projected to expand...
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
June 26, 2023 07:30 ET
|
OpGen, Inc.
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants for the diagnosis of antibiotic resistant bacteria.The opposition division of...